All In Biotech

Investigational drug · Phase 3

B001

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Neuromyelitis Optica Spectrum Disorders.

Phase 3

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

19

Any phase or sponsor naming "B001"

First trial start

2024

Jul 17, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "B001", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Neuromyelitis Optica Spectrum Disorders

Largest trials

Live from ClinicalTrials.gov: studies naming "B001" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 17 on PubMed

Also in development for Neuromyelitis Optica Spectrum Disorders

  • GlucocorticoidsPhase 37 trials

    Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease

  • divozilimabPhase 32 trials

    Biocad · Neuromyelitis Optica Spectrum Disorders, Systemic Scleroderma

  • JYP0061Experimental Drug GroupPhase 22 trials

    Guangzhou JOYO Pharma Co., Ltd · Moderate-to-severe Atopic Dermatitis, Neuromyelitis Optica Spectrum Disorders

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.